Edward J. Olhava

8.5k citations

27 papers · 3.8k indexed · 2 hit papers · h-index 19

Co-authors: H. Martin Seidel Matthew Mangan Eicke Latz Gary D. Glick William Roush David A. Evans Jeffrey S. Johnson Robert A. Copeland
Topics: Epigenetics and DNA Methylation (14 papers)Acute Myeloid Leukemia Research (12 papers)Cancer-related gene regulation (11 papers)
Cited by: Hematology Biological Psychiatry Molecular Biology
Journals: Journal of the American Chemical Society Angewandte Chemie International Edition Blood
Partner nations: United States United Kingdom Canada

In The Last Decade

Edward J. Olhava

27 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting the NLRP3 inflammasome in inflammatory diseases

2018 1.5k citations Matthew Mangan, Edward J. Olhava et al. Nature Reviews Drug Discovery profile →
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →

Peers

Countries citing papers authored by Edward J. Olhava

Since Specialization

Citations

This map shows the geographic impact of Edward J. Olhava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward J. Olhava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward J. Olhava more than expected).

Fields of papers citing papers by Edward J. Olhava

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward J. Olhava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward J. Olhava. The network helps show where Edward J. Olhava may publish in the future.

Co-authorship network of co-authors of Edward J. Olhava

This figure shows the co-authorship network connecting the top 25 collaborators of Edward J. Olhava. A scholar is included among the top collaborators of Edward J. Olhava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward J. Olhava. Edward J. Olhava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases 2018 ·Nature Reviews Drug Discovery ·Matthew Mangan,Edward J. Olhava,William Roush,H. Martin Seidel,Gary D. Glick,Eicke Latz	349
2	Targeting the NLRP3 inflammasome in inflammatory diseasesbreakdown → 2018 ·Nature Reviews Drug Discovery ·Matthew Mangan,Edward J. Olhava,William Roush,H. Martin Seidel,Gary D. Glick,Eicke Latz	1460
3	Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia 2017 ·Molecular Cancer Therapeutics ·Carly Campbell,(unknown),David A. Drubin,Timothy M. Thomson,(unknown),(unknown),Nigel J. Waters,Edward J. Olhava,Roy M. Pollock,J. Joshua Smith,Robert A. Copeland,Stephen J. Blakemore,Kathrin M. Bernt,Scott R. Daigle	46
4	Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human 2015 ·Cancer Chemotherapy and Pharmacology ·Nigel J. Waters,Sherri Smith,Edward J. Olhava,Kenneth W. Duncan,Richard D. E. Burton,(unknown),(unknown),Roy M. Pollock,Mikel P. Moyer,Richard Chesworth	23
5	Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target 2015 ·Journal of Controlled Release ·Nigel J. Waters,Scott R. Daigle,(unknown),Aravind Basavapathruni,Carly Campbell,(unknown),(unknown),Edward J. Olhava,Roy M. Pollock,(unknown),(unknown)	21
6	DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Christine R. Klaus,(unknown),Danielle Johnston,(unknown),J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Edward J. Olhava,Margaret Porter Scott,Roy M. Pollock,Scott R. Daigle,Alejandra Raimondi	96
7	Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor 2014 ·Biopharmaceutics & Drug Disposition ·Aravind Basavapathruni,Edward J. Olhava,Scott R. Daigle,(unknown),Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,(unknown),Victoria M. Richon,Roy M. Pollock,Robert A. Copeland,Mikel P. Moyer,Richard Chesworth,Paul G. Pearson,Nigel J. Waters	64
8	Potent inhibition of DOT1L as treatment of MLL-fusion leukemiabreakdown → 2013 ·Blood ·Scott R. Daigle,Edward J. Olhava,(unknown),Aravind Basavapathruni,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Nigel J. Waters,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Roy M. Pollock	546
9	Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l 2013 ·Blood ·Aniruddha J. Deshpande,Liying Chen,Maurizio Fazio,Amit Sinha,Kathrin M. Bernt,Deepti Banka,(unknown),Jenny Chia-Chen Chang,Edward J. Olhava,Scott R. Daigle,Victoria M. Richon,Roy M. Pollock,Scott A. Armstrong	131
10	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L 2012 ·Chemical Biology & Drug Design ·Aravind Basavapathruni,Lei Jin,Scott R. Daigle,Christina R. Majer,(unknown),Tim J. Wigle,Kevin W. Kuntz,Richard Chesworth,Roy M. Pollock,Margaret Porter Scott,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Edward J. Olhava	114
11	Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l 2012 ·Leukemia ·Liang Chen,Anagha Deshpande,Deepti Banka,Kathrin M. Bernt,Sérgio Dias,Christian Buske,Edward J. Olhava,Scott R. Daigle,Victoria M. Richon,Roy M. Pollock,Scott A. Armstrong	101
12	Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. 2012 ·Blood ·Roy M. Pollock,Scott R. Daigle,(unknown),Aravind Basavapathruni,Lei Jin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Edward J. Olhava	3
13	Targeting epigenetic enzymes for drug discovery 2010 ·Current Opinion in Chemical Biology ·Robert A. Copeland,Edward J. Olhava,Margaret Porter Scott	87
14	Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit 2010 ·Biochemical Journal ·Christopher Blackburn,Kenneth M. Gigstad,Paul Hales,Khristofer Garcia,Matthew D. Jones,Frank J. Bruzzese,(unknown),(unknown),Teresa A. Soucy,Darshan S. Sappal,Nancy J. Bump,Edward J. Olhava,Paul Fleming,Lawrence R. Dick,Christopher Tsu,Michael D. Sintchak,Jonathan L. Blank	129
15	Total Synthesis of (+)‐Azaspiracid‐1. Part I: Synthesis of the Fully Elaborated ABCD Aldehyde 2007 ·Angewandte Chemie International Edition ·David A. Evans,Lisbet Kværnø,Jason A. Mulder,Brian Raymer,Travis B. Dunn,André M. Beauchemin,Edward J. Olhava,Martin Juhl,Katsuji Kagechika	34
16	Total Synthesis of (+)‐Azaspiracid‐1. Part II: Synthesis of the EFGHI Sulfone and Completion of the Synthesis 2007 ·Angewandte Chemie International Edition ·David A. Evans,Travis B. Dunn,Lisbet Kværnø,André M. Beauchemin,Brian Raymer,Edward J. Olhava,Jason A. Mulder,Martin Juhl,Katsuji Kagechika,David A. Favor	44
17	Total Synthesis of (+)‐Azaspiracid‐1. Part I: Synthesis of the Fully Elaborated ABCD Aldehyde 2007 ·Angewandte Chemie ·David A. Evans,Lisbet Kværnø,Jason A. Mulder,Brian Raymer,Travis B. Dunn,André M. Beauchemin,Edward J. Olhava,Martin Juhl,Katsuji Kagechika	10
18	Enantioselective Synthesis of Dihydropyrans. Catalysis of Hetero Diels−Alder Reactions by Bis(oxazoline) Copper(II) Complexes 2000 ·Journal of the American Chemical Society ·David A. Evans,Jeffrey S. Johnson,Edward J. Olhava	260
19	ChiralC2-Symmetric CuII Complexes as Catalysts for Enantioselective Hetero-Diels-Alder Reactions 1998 ·Angewandte Chemie International Edition ·David A. Evans,Edward J. Olhava,Jeffrey S. Johnson,Jacob M. Janey	132
20	ChiraleC2-symmetrische CuII-Komplexe als Katalysatoren für enantioselektive Hetero-Diels-Alder-Reaktionen 1998 ·Angewandte Chemie ·David A. Evans,Edward J. Olhava,Jeffrey S. Johnson,Jacob M. Janey	26

About Edward J. Olhava

Edward J. Olhava is a scholar working on Hematology, Environmental Chemistry and Biotechnology, having authored 27 papers that have together received 3.8k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (14 papers), Acute Myeloid Leukemia Research (12 papers) and Cancer-related gene regulation (11 papers). The work is most often cited by research in Hematology (492 citations), Biological Psychiatry (104 citations) and Molecular Biology (2.7k citations). Edward J. Olhava has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include H. Martin Seidel, Matthew Mangan, Eicke Latz, Gary D. Glick, William Roush, David A. Evans, Jeffrey S. Johnson, Robert A. Copeland, Margaret Porter Scott and Roy M. Pollock. Their work appears in journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact